Leonid Timashev
Stock Analyst at RBC Capital
(4.04)
# 456
Out of 5,148 analysts
158
Total ratings
53.24%
Success rate
10.98%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVB Nuvation Bio | Maintains: Outperform | $12 → $13 | $4.43 | +193.45% | 5 | Mar 3, 2026 | |
| BHVN Biohaven | Maintains: Outperform | $22 → $23 | $10.77 | +113.56% | 15 | Mar 3, 2026 | |
| EXEL Exelixis | Maintains: Sector Perform | $46 → $43 | $40.37 | +6.51% | 4 | Mar 2, 2026 | |
| ONC BeOne Medicines AG | Maintains: Outperform | $417 → $425 | $295.28 | +43.93% | 6 | Feb 27, 2026 | |
| ALKS Alkermes | Maintains: Outperform | $47 → $45 | $29.96 | +50.20% | 6 | Feb 26, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $191 → $195 | $186.49 | +4.56% | 4 | Feb 25, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $219 → $222 | $165.00 | +34.55% | 16 | Feb 24, 2026 | |
| CYTK Cytokinetics | Maintains: Outperform | $95 → $101 | $60.26 | +67.61% | 7 | Feb 20, 2026 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $49 | $34.25 | +43.07% | 5 | Feb 18, 2026 | |
| CMPS COMPASS Pathways | Maintains: Outperform | $21 → $22 | $6.76 | +225.44% | 6 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $61 → $73 | $57.60 | +26.74% | 3 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $30.83 | +52.45% | 9 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $13 | $6.89 | +88.68% | 3 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $77 → $140 | $99.15 | +41.20% | 2 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $197 → $200 | $145.61 | +37.35% | 8 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 | $17.70 | +272.88% | 15 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $1.45 | +246.02% | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $13 | $10.33 | +25.85% | 10 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $1.32 | +203.03% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $50 | $29.17 | +71.41% | 15 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $19 | $11.83 | +60.61% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $27 → $11 | $5.50 | +100.00% | 2 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $5.67 | +129.28% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $4.15 | +20.48% | 1 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $16 | $5.25 | +204.76% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $0.63 | +377.94% | 1 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $98.66 | -29.05% | 1 | Jan 23, 2025 |
Nuvation Bio
Mar 3, 2026
Maintains: Outperform
Price Target: $12 → $13
Current: $4.43
Upside: +193.45%
Biohaven
Mar 3, 2026
Maintains: Outperform
Price Target: $22 → $23
Current: $10.77
Upside: +113.56%
Exelixis
Mar 2, 2026
Maintains: Sector Perform
Price Target: $46 → $43
Current: $40.37
Upside: +6.51%
BeOne Medicines AG
Feb 27, 2026
Maintains: Outperform
Price Target: $417 → $425
Current: $295.28
Upside: +43.93%
Alkermes
Feb 26, 2026
Maintains: Outperform
Price Target: $47 → $45
Current: $29.96
Upside: +50.20%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Outperform
Price Target: $191 → $195
Current: $186.49
Upside: +4.56%
Axsome Therapeutics
Feb 24, 2026
Maintains: Outperform
Price Target: $219 → $222
Current: $165.00
Upside: +34.55%
Cytokinetics
Feb 20, 2026
Maintains: Outperform
Price Target: $95 → $101
Current: $60.26
Upside: +67.61%
IDEAYA Biosciences
Feb 18, 2026
Reiterates: Outperform
Price Target: $49
Current: $34.25
Upside: +43.07%
COMPASS Pathways
Feb 18, 2026
Maintains: Outperform
Price Target: $21 → $22
Current: $6.76
Upside: +225.44%
Jan 21, 2026
Maintains: Outperform
Price Target: $61 → $73
Current: $57.60
Upside: +26.74%
Jan 21, 2026
Maintains: Outperform
Price Target: $44 → $47
Current: $30.83
Upside: +52.45%
Jan 21, 2026
Maintains: Outperform
Price Target: $22 → $13
Current: $6.89
Upside: +88.68%
Jan 21, 2026
Maintains: Outperform
Price Target: $77 → $140
Current: $99.15
Upside: +41.20%
Jan 21, 2026
Maintains: Outperform
Price Target: $197 → $200
Current: $145.61
Upside: +37.35%
Jan 20, 2026
Maintains: Outperform
Price Target: $66
Current: $17.70
Upside: +272.88%
Dec 19, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $1.45
Upside: +246.02%
Nov 20, 2025
Upgrades: Outperform
Price Target: $6 → $13
Current: $10.33
Upside: +25.85%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $1.32
Upside: +203.03%
Nov 7, 2025
Maintains: Outperform
Price Target: $49 → $50
Current: $29.17
Upside: +71.41%
Nov 6, 2025
Maintains: Outperform
Price Target: $18 → $19
Current: $11.83
Upside: +60.61%
Oct 31, 2025
Downgrades: Sector Perform
Price Target: $27 → $11
Current: $5.50
Upside: +100.00%
Aug 8, 2025
Maintains: Outperform
Price Target: $12 → $13
Current: $5.67
Upside: +129.28%
Jun 20, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $4.15
Upside: +20.48%
Jun 3, 2025
Maintains: Outperform
Price Target: $15 → $16
Current: $5.25
Upside: +204.76%
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $0.63
Upside: +377.94%
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $98.66
Upside: -29.05%